Please assess the completion status of the following clinical trial:

Trial Title: Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients age 18 and older who underwent an allogeneic hematopoietic stem cell transplantation.~* Patients are required to have biopsy proven GVHD.~* Patients must have active acute GVHD requiring systemic immune suppressive therapy and that failed or did not respond to first line of therapy.~  * First line therapy needs to be a minimum of corticosteroids, methylprednisolone of 1.6mg/kg/day or prednisone of 2mg/kg/day, alone or combined to other agent.~ * Failure of GVHD therapy is defined as flare of signs and symptoms of acute GVHD or progression of GVHD grade after at least 72 hours from starting therapy.~ * No response to GVHD treatment (corticosteroids ± other agent) after a minimum of 7 days of treatment.~* Patient must be able to give informed consent.~Exclusion Criteria:~* Intolerance or allergy to Tocilizumab~* Active uncontrolled infection requiring ongoing treatment with antifungals, antibiotics or anti-viral drugs.~* Relapsed/persistent malignancy requiring rapid immune suppression withdrawal.~* Liver enzymes: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \> 3x upper limit of normal.~* Patients with severe sinusoidal obstruction syndrome who in the judgment of the treating physician are not expected to have normalized bilirubin by day 56 after enrollment.~* Serum bilirubin \> 2x upper limit of normal.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): Drug: Tocilizumab~Other Names:~Actemra~Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.

Based on this trial design, predict the completion outcome and termination type (if applicable).